The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.

File Description SizeFormat 
9466-144141-1-PB.pdfPublished version7.87 MBAdobe PDFView/Open
Title: The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.
Authors: Trousil, S
Kaliszczak, M
Schug, Z
Nguyen, Q
Tomasi, G
Favicchio, R
Brickute, D
Fortt, R
Twyman, FJ
Carroll, L
Kalusa, A
Navaratnam, N
Adejumo, T
Carling, D
Gottlieb, E
Aboagye, EO
Item Type: Journal Article
Issue Date: 19-May-2016
Date of Acceptance: 25-Apr-2016
URI: http://hdl.handle.net/10044/1/33061
DOI: https://dx.doi.org/10.18632/oncotarget.9466
ISSN: 1949-2553
Publisher: Impact Journals
Start Page: 37103
End Page: 37120
Journal / Book Title: Oncotarget
Volume: 7
Issue: 24
Copyright Statement: © 2016 The Authors. Published by Impact Journals under a Creative Commons Attribution 3.0 license (http://creativecommons.org/licenses/by/3.0/)
Sponsor/Funder: Cancer Research UK
Funder's Grant Number: C2536/A16584
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Cell Biology
choline kinase
metabolism
mitochondrial function
cancer
positron emission tomography
POSITRON-EMISSION-TOMOGRAPHY
MAGNETIC-RESONANCE-SPECTROSCOPY
MAMMARY EPITHELIAL-CELLS
BREAST-CANCER
PHOSPHOLIPID-METABOLISM
PROSTATE-CANCER
MALIGNANT-TRANSFORMATION
ALPHA
PHOSPHATIDYLCHOLINE
PROLIFERATION
cancer
choline kinase
metabolism
mitochondrial function
positron emission tomography
Publication Status: Published
Appears in Collections:Division of Surgery
Clinical Sciences
Division of Cancer
Molecular Sciences
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx